Glenmede Trust Co. NA Sells 46,231 Shares of Cencora, Inc. $COR

Glenmede Trust Co. NA lowered its holdings in shares of Cencora, Inc. (NYSE:COR) by 38.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 73,840 shares of the company’s stock after selling 46,231 shares during the period. Glenmede Trust Co. NA’s holdings in Cencora were worth $23,196,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Kemnay Advisory Services Inc. purchased a new position in Cencora in the 4th quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new stake in Cencora during the 4th quarter valued at approximately $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora during the fourth quarter valued at approximately $27,000. Archer Investment Corp raised its position in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora in the fourth quarter worth $29,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the transaction, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.38% of the stock is currently owned by company insiders.

Cencora Trading Up 0.1%

COR stock opened at $312.40 on Friday. The firm has a fifty day moving average price of $289.36 and a 200 day moving average price of $315.60. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The firm has a market cap of $60.78 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.8 earnings per share for the current fiscal year.

Cencora announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s payout ratio is 18.40%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on COR. Barclays dropped their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. UBS Group boosted their price target on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. William Blair began coverage on shares of Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Robert W. Baird cut their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Evercore set a $360.00 target price on Cencora in a report on Wednesday, April 8th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.